Maro Ohanian

Maro Ohanian is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. Her research focuses on acute myeloid leukemia, myelodysplastic syndromes, and other hematological malignancies, with a particular emphasis on novel pharmacotherapeutic combinations and clinical trial design. Her recent work includes investigating venetoclax-based regimens, such as cladribine with low-dose cytarabine and venetoclax, and azacitidine combined with venetoclax for high-risk myeloid neoplasia. She has also published on hyper-CVAD plus blinatumomab for Philadelphia chromosome-negative acute lymphoblastic leukemia and on sotatercept for pulmonary hypertension associated with myeloproliferative neoplasms. Her research further addresses socioeconomic and racial disparities in leukemia clinical trial access.